Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies.
Significant progress has been made in reducing the risk of pathogen transmission to transfusion recipients. Nonetheless, there remains a continuing risk of transmission of viruses, bacteria, protozoa, and prions to recipients. These include many of the viruses for which specific screening tests exist as well as pathogens for which testing is currently not being done, including various species of bacteria, babesiosis, variant Creutzfeld-Jacob disease, hepatitis A virus, human herpes virus 8, chikungunya virus, Chagas disease, and malaria. Pathogen inactivation (PI) technologies potentially provide an additional way to protect the blood supply from emerging agents and also provide additional protection against both known and as-yet-unidentified agents. However, the impact of PI on product quality and recipient safety remains to be determined. The purpose of this consensus conference was to bring together international experts in an effort to consider the following issues with respect to PI: implementation criteria; licensing requirements; blood service and clinical issues; risk management issues; cost-benefit impact; and research requirements. These proceedings are provided to make available to the transfusion medicine community the considerable amount of important information presented at this consensus conference.
Medical, Scientific, and Research Affairs, Canadian Blood Services, Hamilton, Edmonton and Toronto, Canada. webertk@mcmaster.ca
Kathryn E
KE
Webert
Christine M
CM
Cserti
Judy
J
Hannon
Yulia
Y
Lin
Katerina
K
Pavenski
Jacob M
JM
Pendergrast
Morris A
MA
Blajchman
D000818:Animals; D000890:Anti-Infective Agents / Q000633:toxicity; D001792:Blood Platelets / Q000187:drug effects / Q000382:microbiology; D001803:Blood Transfusion / Q000191:economics / Q000639:trends; D017848:Blood-Borne Pathogens; D019411:Clinical Laboratory Techniques / Q000191:economics / Q000379:methods*; D003362:Cost-Benefit Analysis; D003657:Decision Making; D004912:Erythrocytes / Q000187:drug effects / Q000382:microbiology; D005060:Europe; D006801:Humans; D013677:Medical Laboratory Science / Q000191:economics / Q000331:legislation & jurisprudence / Q000639:trends; D050296:Microbial Viability / Q000276:immunology; D011634:Public Health / Q000331:legislation & jurisprudence; D065227:Transfusion Reaction; D014180:Transplantation; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
D000890:Anti-Infective Agents